Takeda Outlicenses Two CCR5 Antagonists To Newly Formed Tobira
This article was originally published in PharmAsia News
Executive Summary
A new chemokine receptor 5 antagonist candidate licensed this week to Tobira Therapeutics by Takeda could provide a dosing advantage over other CCR5 antagonists in development, such as Pfizer's maraviroc and Schering-Plough's vicriviroc, according to Tobira CEO James Sapirstein
You may also be interested in...
Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists
Both Schering’s vicriviroc and Incyte’s INCB9471 CCR5 antagonist candidates to treat HIV beat placebo in Phase II trials.
Pfizer’s Maraviroc Deemed “Approvable” By FDA
Pfizer says it is working with FDA to finalize product labeling for the HIV treatment as soon as possible.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).